Chronic Ingestion of H1-Antihistamines Increase Progression of Atherosclerosis in Apolipoprotein E-/- Mice by Raveendra, Vineesh V. et al.
Chronic Ingestion of H1-Antihistamines Increase
Progression of Atherosclerosis in Apolipoprotein E-/-
Mice
Vineesh V. Raveendran1, Donald D. Smith1, Xiaoyu Tan1, Matthew E. Sweeney1, Gregory A. Reed2,
Colleen A. Flynn2, Ossama W. Tawfik3, Ginger Milne4, Kottarappat N. Dileepan1*
1 Division of Allergy, Clinical Immunology & Rheumatology, Department of Medicine, University of Kansas Medical Center, Kansas City, Kansas, United States of America,
2 Department of Pharmacology, Toxicology and Therapeutics, University of Kansas Medical Center, Kansas City, Kansas, United States of America, 3 Department of
Pathology and Laboratory Medicine, University of Kansas Medical Center, Kansas City, Kansas, United States of America, 4 Vanderbilt University Medical Center, Nashville,
Tennessee, United States of America
Abstract
Although increased serum histamine levels and H1R expression in the plaque are seen in atherosclerosis, it is not known
whether H1R activation is a causative factor in the development of the disease, or is a host defense response to atherogenic
signals. In order to elucidate how pharmacological inhibition of histamine receptor 1 (H1R) signaling affects atherogenesis,
we administered either cetirizine (1 and 4 mg/kg. b.w) or fexofenadine (10 and 40 mg/kg. b.w) to ApoE2/2 mice maintained
on a high fat diet for three months. Mice ingesting a low dose of cetirizine or fexofenadine had significantly higher plaque
coverage in the aorta and cross-sectional lesion area at the aortic root. Surprisingly, the higher doses of cetirizine or
fexofenadine did not enhance atherosclerotic lesion coverage over the controls. The low dose of fexofenadine, but not
cetirizine, increased serum LDL cholesterol. Interestingly, the expression of iNOS and eNOS mRNA was increased in aortas of
mice on high doses of cetirizine or fexofenadine. This may be a compensatory nitric oxide (NO)-mediated vasodilatory
mechanism that accounts for the lack of increase in the progression of atherosclerosis. Although the administration of
cetirizine did not alter blood pressure between the groups, there was a positive correlation between blood pressure and
lesion/media ratio at the aortic root in mice receiving the low dose of cetirizine. However, this association was not observed
in mice treated with the high dose of cetirizine or either doses of fexofenadine. The macrophages or T lymphocytes
densities were not altered by low doses of H1-antihistamines, whereas, high doses decreased the number of macrophages
but not T lymphocytes. The number of mast cells was decreased only in mice treated with low dose of fexofenadine. These
results demonstrate that chronic ingestion of low therapeutic doses of cetirizine or fexofenadine enhance progression of
atherosclerosis.
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Introduction
Histamine, a major product of mast cells, regulates many vital
physiological functions including vasodilation, allergic response
and neurotransmission [1–3]. The effects of histamine are
mediated through a family of four G-protein coupled receptors
(GPCR), histamine H1 receptor (H1R), H2R, H3R and H4R [4].
The role of histamine and H1R in the pathophysiology of
atherosclerosis has been studied, with special emphasis on its
potential proatherogenic role [5,6]. In this regard, increased
expression of H1R in human atheromas and elevated histamine
content in atherosclerotic plaques in ApoE2/2 mice have been
reported [6,7]. Furthermore, an elevated serum level of histamine
is found to be associated with hypertension [8], atherosclerosis [9],
and diabetes [10]. We have previously shown that histamine
stimulates the production of both proatherogenic cytokines, such
as IL-6, IL-8, and anti-atherogenic prostanoids, PGI2 and PGE2,
in human coronary artery endothelial cells (HCAEC) through
H1R activation [11–14]. Although, histamine and H1R signaling
are associated with cardiovascular events, it is not known whether
H1R activation is proatherogenic or is a protective immune
response to atherogenesis. However, previous reports show that
first generation H1-antihistamines like chlorpheniramine [15], and
mepyramine [16] reduce atherogenesis in pigs and ApoE2/2 mice,
respectively. It is noteworthy that, recent studies from our
laboratory demonstrated that new generation H1-antihistamines,
cetirizine and fexofenadine, increase high fat diet-induced hepatic
steatosis in C57Bl/6 mice [17]. The objective of this study was to
examine the effect of chronic ingestion of these H1-antihistamines
on progression of atherosclerosis in ApoE2/2 mice.
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Methods
Animals and treatments
Eight week old male B6/129P2-Apoetm1Unc/J mice (ApoE2/
2), stock number 002052 (Jackson Laboratories, Bar Harbor, ME)
were randomly assigned into ‘placebo’, ‘cetirizine low’ (1 mg/kg
b.w.), ‘cetirizine high’ (4 mg/kg b.w.), fexofenadine low (10 mg/kg
b.w.), or fexofenadine high (40 mg/kg b.w.) groups. All mice were
individually housed and fed ad libitum a Western diet (Harlan
Teklad, Madison, WI) for three months. The experiments
evaluating the effect of low dose cetirizine were carried out three
times along with untreated controls. Data of these three
experiments were combined for certain parameters as indicated
in the results section. All animals had free access to either plain
water or water containing cetirizine (5 mg/L and 20 mg/L,
Sigma-Aldrich, St. Louis, MO) or fexofenadine (50 mg/L and
200 mg/L) to achieve an approximate daily intake of 1 and 4 mg
cetirizine/kg b.w., or 10 and 40 mg/kg b.w. fexofenadine,
respectively, assuming mice ingest approximately 5 mL of
water/day. Fexofenadine solution was prepared by grinding
Allegra tablets (over-the-counter, 180 mg/tablets) and filtering
through Whatman filter paper to remove insoluble contents.
Concentrations of H1-antihistmines were equivalent to the
therapeutic doses for adult humans adjusted for the mouse body
surface area [18]. The investigation conformed to the Guide for
the Care and Use of Laboratory Animals published by the US
National Institutes of Health, and was approved by the
Institutional Animal Care and Use Committee of the University
of Kansas Medical Center.
Collection of urine, blood, heart and aorta
Twenty four hour urine samples were collected by placing each
mouse in a metabolic cage (Tecniplast, Rochester, NY). Blood
samples were collected from the retro-orbital sinus under
anesthesia at the time of necropsy. Mice were euthanized using
isoflurane (Abbott, North Chicago, IL) inhalation followed by
opening the thoracic cavity. The heart and aorta were collected
and processed for cross-sectional analyses of plaque area in the
aortic root, and for en face analyses, as described previously
[19,20].
Assessment of atherosclerotic plaques
Histological sections of the root of the aorta were stained with
hematoxylin/eosin (H&E). Light microscopy was performed to
evaluate the atherosclerotic changes. Histological sections on the
glass slides were scanned using the Aperio Scanscope System
(Vista, CA) to create virtual slides for quantitative evaluation. The
images were transferred to Adobe Photoshop CS4 and lesion area
at aortic root was measured using the lasso and analysis tool and
presented as mm2. The lesion area is normalized to the underlying
media area.
Aortas were prepared en face to quantify area of lesion coverage
as described previously [19]. Briefly, the entire aorta was isolated
from the arch to the aortic-iliac bifurcation. After removing the
adipose tissue, the aorta was placed in 10% neutral buffered
formalin overnight. The aorta was then opened lengthwise, and
pinned flat in a wax bottomed dissecting pan. The tissue was
stained for 15 minutes with 0.5% Sudan IV solution in acetone
and 70% ethanol (1:1), then decolorized using 80% ethanol, and
washed gently with water for 45–60 minutes. Each en face
preparation was digitally imaged and transferred to Adobe
Photoshop CS4 for the quantification of lesion coverage. To
facilitate the conversion of pixels into mm2, a 10 mm scale was
placed next to each aorta during photography. Lesions were
delineated by tracing their contours with the Lasso tool and
analyzed for the area of each plaque. After measuring the lesion
areas, the percentage area of lesion coverage was calculated based
on the total area of the aorta.
Immunofluorescence staining of H1R in aortic roots
H1R protein expression in the atheroma was assessed in
histological sections by using anti-H1R antibody (Alomone Labs,
Israel) followed by Alexafluor-488 staining for immunofluores-
cence detection. Nucleus was counterstained with DAPI. Images
were captured and analyzed using Leica TCS SPE Confocal
Microscope as well as a Nikon 80i fluorescent microscope.
Integrated density of H1R fluorescence was measured using
Adobe Photoshop CC, Adobe Corporation.
Quantification of T lymphocytes, macrophages and mast
cells, and expression of scavenger receptor CD36
T lymphocytes (CD3+), macrophages (Mac3+) and mast cells
(CD117+ or toluidine blue+) were quantified after immunostaining
with anti-CD3 (DAKO, Carpinteria, CA), anti-Mac3 and anti-
CD117 (eBioscience, San Diego, CA), respectively. The expression
of CD36 was quantified using anti-CD36 antibody (Abcam,
Cambridge, MA). After completion of immunohistochemical
staining, slides were placed on the ACIS automated imaging
system (DAKO) for quantifying the tissue staining. The system
consists of an automated microscope, a three-chip Sony progres-
sive scan camera, a computer, and Windows NT 4.0 workstation
software interface. Each slide was scanned by the robotic
microscope. The ACIS system captures images from each slide,
quantifies staining in selected regions, and presents a numerical
score. It was used to quantify immunohistochemical staining of
percent positive cells for CD3 [19] and staining intensity for Mac3.
An average score for all selected areas was then calculated for each
marker. Mast cells were identified as toluidine blue+ and CD117+
cells and enumerated in three to five high power fields. The
intensity of CD36 staining in aortic atheromas was graded on a
scale from zero to three.
Messenger RNA expressions in the aorta
Total RNA was extracted from the aorta of four animals from
each group using TRlzol Reagent applying Phase Lock Gel-Heavy
protocol at the University of Kansas Medical Center’s microarray
facility. Total RNA was reverse transcribed into first-strand cDNA
using a High-Capacity cDNA Reverse Transcription Kit following
the manufacturer’s procedure. Quantitative real-time RT-PCR
was performed using the ABI7500 Real-Time PCR system
(Applied Biosystems). The amplification reactions were performed
in 25 ml total volume containing SYBR Green PCR Master Mix
with respective primers and 5 ml of cDNA of each mouse. The
primers were designed using Primer Express Software v3.0
(Applied Biosystems). The sequences of primers used are provided
in Table S1. The mRNA expressions of genes of each sample were
normalized with their mRNA expression of b-actin. After
normalization, the fold change of mRNA of each gene relative
to one sample from the control group was calculated by
comparative DDCT method.
Blood pressure monitoring
To obtain a measure of vascular functions associated with the
treatments, blood pressure, heart rate and blood flow were
measured at the end of experiment using a non-invasive tail cuff
method (CODA 6, Kent Scientific). After restraining the mouse in
a plastic holder, a small occlusion cuff and a Volume Pressure
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Recording (VPR) cuff were applied to the base of the tail. Fifteen
cycles of BP readings were taken while six animals were
simultaneously kept on a warming platform in a quiet, low lighted
and low sensory environment. Animals were acclimated to the
experimental protocol for 3 sessions before actual blood pressure
measurements were recorded. The BP parameters and aortic
plaque occlusion ratios were analyzed for correlation.
Serum chemistry, lipid profiles and cytokine array
Serum chemistry, lipid profile and cytokine array were analyzed
at Veterinary Laboratory Resources, Overland Park, KS and
IDEXX Preclinical Research Services, West Sacramento, CA.
Prostaglandin I2 and thromboxane A2 metabolites in the
urine
Urine samples were purified and the levels of 11-dehydro
thromboxane B2 and 2, 3-dinor-6-keto prostaglandin F1a were
quantified by gas chromatography-mass spectrometry (GC-MS) at
Figure 1. Effect of H1-antihistamines on atherosclerotic plaque development in the aorta. ApoE2/2 mice maintained on a high fat diet
were administered with cetirizine (1 and 4 mg/kg b.w) or fexofenadine (10 and 40 mg/kg b.w.) for 3 months in the drinking water. ApoE2/2 mice
receiving plain water served as placebo controls. Pl, placebo; C.L, cetirizine low; C.H, cetirizine high; F.L, fexofenadine low; F.H, fexofenadine high.
Panel (A) represents images of en face preparations and (B) is the quantification of the percentage area of plaque coverage in the aorta.
Representative images of the H & E stained cross-sections of the aortic root (C), and quantification of lesion area at the aortic root (D). Ao, aorta; PuAo,
pulmonary artery. The ‘‘n’’ for Pl and C.L is the sum of mice used in three independent experiments. The ‘‘n’’ for C.H, F.L and F.H derived from a single
experiment. Data points presented in B and D are mean 6 SEM. *p,0.05 vs. control.
doi:10.1371/journal.pone.0102165.g001
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the Jason. D. Morrow Laboratory, Vanderbilt University Medical
Center, Nashville, TN or by 11-dehydro thromboxane B2 and 6-
keto prostaglandin F1a EIA kits (Cayman Chemicals, MI). The
values for the prostanoid metabolites were normalized to
creatinine levels.
Histamine measurements in urine
Urine samples were analyzed for histamine levels by ELISA
(SPI Bio, France) according to manufacturers’ protocol.
Cetirizine and fexofenadine levels in the serum
Serum samples collected from 3 untreated control mice and 6
mice treated with either cetirizine or fexofenadine were processed
by solid-phase extraction and analyzed by reverse-phase liquid
chromatography-tandem mass spectrometry (LC-MS/MS) for
quantification of cetirizine or fexofenadine. The analytical
procedure was based on the method of Flynn et al. [21].
Statistical analysis
One-way or Two-way ANOVA were adopted for statistical
analyses, as applicable. Pearson correlation analysis was used to
investigate the relationships between blood pressure variables to
lesion occlusion ratio. Results are presented as mean6SEM and
p,0.05 is considered as significant. GraphPad Software v5.04
(San Diego, CA) was used to perform all the statistical analyses.
Results
Chronic ingestion of low doses cetirizine and
fexofenadine increase atherosclerosis
The results presented in Figure 1A and 1B demonstrate
increased atheroma development in mice ingesting low doses of
cetirizine or fexofenadine as measured by plaque coverage in the
en face preparations. This proatherogenic effect of low doses of
H1-antihistamines is further confirmed by the increased lesion
area in the histological sections of aortic roots (Figure 1C and 1D).
Interestingly, ingestion of the high doses of cetirizine or
fexofenadine (Figure 1A–D) did not significantly enhance athero-
sclerosis over the placebo control.
Cetirizine and fexofenadine do not increase H1R
expression in the atheroma
Chronic ingestion of cetirizine or fexofenadine did not
significantly alter H1R expression in the plaque area as
determined by immunofluorescence analysis (Figure 2A and 2B).
The increase in atherogenesis by low doses of H1-
antihistamines is not associated with macrophage or T
lymphocyte, but with a decrease in mast cell numbers in
the lesions
Increased numbers of T lymphocytes, macrophages and mast
cells have been found to be associated with progression of
atherosclerosis [22–24]. However, despite the increase in athero-
sclerosis in mice treated with the low doses of cetirizine or
fexofenadine, we did not find increased number of macrophages
(Figure 3A and 3B) or T lymphocytes (Figure 3C and 3D) in the
lesions when compared to controls. On the other hand, the lack of
increase in atheroma formation by high doses of cetirizine and
fexofenadine was found to be associated with a decrease in
macrophage population (Figure 3A and 3B). Although low doses of
both H1-antihistasmines reduced mast cell numbers in atheroma,
only the effect of fexofenadine was statistically significant (Figure
3E and 3F).
Histological sections of the aortic root from 10–12 mice from
placebo, low doses of cetirizine and fexofenadine groups were
stained for scavenger receptor CD36 using specific antibody. The
Figure 2. Effect of H1-antihistamines on H1R expression in atherosclerotic plaques. Atherosclerotic lesions around the aortic root of
ApoE2/2 mice were subjected to immunohistochemical analyses for H1R expression with anti-H1R (green) and DAPI (nuclear stain-blue). Panel (A)
represents immunoflourescent staining for placebo (Pl), cetirizine low (C.L), cetirizine high (C.H), fexofenadine low (F.L) and fexofenadine high (F.H).
Panel (B) depicts the integrated density of H1R staining. Magnification 406 at objective. n = 4.
doi:10.1371/journal.pone.0102165.g002
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Figure 3. Effect of H1-antihistamines on recruitment of macrophages, T lymphocytes and mast cells into atheromas. Representative
immunohistochemical images (magnification 200x) and quantitative data depicting the densities of Mac3 positive macrophages (A and B), CD3
positive T lymphocytes (C and D) and toluidine blue positive mast cells (D and E) are presented for placebo (Pl), cetirizine low (C.L), cetirizine high
(C.H), fexofenadine low (F.L) and fexofenadine high (F.H). Results shown are mean 6 SEM. Numbers of animals are indicated in each bar.
doi:10.1371/journal.pone.0102165.g003
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average scoring of the staining in aortic atheromas was similar in
all groups of mice (Fig. 4).
High doses of cetirizine and fexofenadine increases iNOS
and eNOS mRNA expression in aorta
The aortic tissues from mice treated with either the low or high
doses of H1-antihistamines were analyzed for the expression of
selected genes associated with vascular inflammation. The mRNA
expression of COX isoforms were not altered by any of the doses
of H1-antihistamines (Figure 5A and 5B). The expression of iNOS
and eNOS mRNA expression were increased by high doses of
both H1-antihistamines (Figure 5C and 5D). The expression of
Egr1 mRNA was not significantly altered by any dose of cetirizine
or fexofenadine (Figure 5E).
Correlation of blood pressure with lesion/media ratio
The vital parameters were not significantly different between
the groups (Table 1). However, an analysis of correlation
demonstrated that in low dose cetirizine treated mice, systolic,
diastolic and arterial mean pressures were positively correlated
with the lesion/media ratio. This is in contrast with placebo which
showed a negative correlation. In contrast neither high dose of
cetirizine nor any doses of doses of fexofenadine showed a
correlation between BP parameters and the degree of occlusion
(Figure 6).
Serum lipids, chemistry and cytokines
Results of chronic ingestion of cetirizine and fexofenadine on
serum lipids and chemistry are presented in Table 2. The low dose
of cetirizine did not affect serum lipid levels. On the other hand,
the low dose of fexofenadine significantly increased LDL
cholesterol. The levels of creatine phosphokinase (CPK) were
significantly decreased in low doses of both H1-antihistamines.
Alkaline phosphatase (ALP) was increased only in mice ingesting
low dose of fexofenadine.
The serum levels of cytokines and chemokines evaluated using
cytokine array are presented in Table 3. Significant changes were
noted only in IL-1a, macrophage inflammatory protein-1a (MIP-
1a), MIP-3 and growth regulated kinase-a protein (GRO-a) by
either of the H1-antihistamines.
Serum levels of cetirizine and fexofenadine
Animals in all groups consumed similar amounts of water and
food (Data not shown). To evaluate the bioavailability of orally
administered cetirizine and fexofenadine, we analyzed their levels
in serum samples by LC-MS/MS. All animals in the cetirizine-
treated groups had detectable levels of cetirizine with mean
concentration of 190650 ng/ml (n = 8; 4 mice each from
experiment 1 and 2) and 7106146 ng/ml (n = 4, experiment 2)
for mice treated with low dose and high dose cetirizine,
respectively. As expected, cetirizine concentrations in sera of
control mice were below the detectable limits of the assay (,3 ng/
ml). The fexofenadine in serum of mice treated with high dose of
fexofenadine was 8.460.3 ng/ml (n = 4). The serum levels of
fexofenadine in the experiment with low dose of fexofenadine were
not determined.
Effect of H1-antihistamines on PGI2, TxA2 and histamine
The cyclooxygenase pathway has an important influence in
vascular inflammation and atherosclerosis. Of particular interest is
the opposing effects of TxA2 and PGI2 on vascular tone and
atherogenesis [25]. Histamine has been shown to enhance the
expression of COX2 and the production of PGI2 in HCAEC via
H1R activation [12]. To determine whether chronic ingestion of
cetirizine and fexofenadine affect systemic production of TxA2 and
PGI2, we measured the levels of the stable metabolites for TxA2
and PGI2 in the urine. Data presented in Figure 7A and B show
that ingestion of H1-antihistamines does not affect systemic
production of TxA2 or PGI2. Similarly, neither cetirizine nor
fexofenadine affected urinary levels of histamine (Figure 7C).
Discussion
Evidence suggests an important role for histamine and H1R in
coronary artery disease and atherosclerosis [6,7,26]. A recent
report showed that either the treatment with a first generation H1-
antihistamine mepyramine or deletion of H1R gene in ApoE2/2
mice resulted in significant reduction of atherosclerotic lesion
formation [16]. In this present study, we show that oral
administration of human therapeutic doses of cetirizine (1 mg/
kg b.w) or fexofenadine (10 mg/kg b.w) in ApoE2/2 mice for three
months did not reduce progression of atherosclerosis, instead,
increased the atherosclerotic lesion formation. These results are
not in agreement with the antiatherogenic effect recently reported
for mepyramine [16]. We recognize the fact that H1R gene
Figure 4. Effect of low doses of cetirizine and fexofenadine on
CD36 expression. Representative immunohistochemical images (A–C,
magnification at 200x) of scavenger receptor CD36 are presented.
Placebo (Pl), cetirizine low (C.L), fexofenadine low (F.L). No significant
difference in the intensity was noted between groups by a grading of
scale zero to three.
doi:10.1371/journal.pone.0102165.g004
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deletion was able to mimic the effect of mepyramine in the earlier
study. We believe that distinct pharmacological features of
mepyramine and those of cetirizine and fexofenadine, and
differences in the doses of H1-antihistamines used, might be the
contributing factors for the disparity between the present and
previous report [16].
Cetirizine and fexofenadine are extensively used for treating
allergic diseases. To the best of our knowledge, this is the first study
which compared the effects of therapeutic doses of two commonly
used H1-antihistamines on the progression of atherosclerosis in the
ApoE2/2 mouse model. In this study, we demonstrate that lesion
formation in the entire aorta was exacerbated by low dose H1-
antihistamines. In addition, low doses of these H1-antihistamines
increased lesion thickness and area at the aortic root. To our
surprise, high doses of cetirizine or fexofenadine did not enhance
atheroma formation compared to controls. This can be explained
by the unique properties of H1R inverse agonists, which depends
on the affinity and the concentration of drug [27]. The lower doses
of H1-antihistamines may not be sufficient to completely block
H1R signaling especially if H1 receptors are over expressed. This
contention is supported by the finding that low concentrations of
both cetirizine and fexofenadine seem to enhance H1R expression
compared to control as well as their respective high dose
counterparts (Figure 2A). In the case of high doses of H1-
antihistamines, more efficient blockade of H1R signaling should
be expected. It is possible that further increases in the doses of
these antihistamines may even reduce atherogenesis. This may
explain the discrepancy between our findings and the previous
report demonstrating reduced atherogenesis by mepyramine or
H1R deletion in ApoE2/2 mice. Also, unique chemical and
pharmacological properties of these different H1-antihistamines
secondary to antagonizing H1R signaling may result in their
adverse outcomes.
A second possibility is that high doses of these H1-antihista-
mines switch H1R into an inactive conformation because of their
inverse agonistic properties. The molecular basis of the mode of
action of second generation antihistamines demonstrates unique
receptor binding characteristics, since they bind to H1R as inverse
agonists rather than antagonists [28]. Since cetirizine and
fexofenadine are inverse H1R agonists, they can generate opposite
pharmacological effects compared to the agonist. Thus, in the
absence of agonist binding, an inverse agonist can induce
overwhelming negative impacts, especially under in vivo condi-
tions with chronic blockade of the receptor signaling. It is possible
that higher doses of inverse agonists may irreversibly modulate the
receptor signaling or promiscuously bind to other histamine
receptors such as H4R [29]. This may explain the results of
increased atherogenic effects of cetirizine and fexofenadine at the
low doses, and not at the high doses.
Atherogenesis involves increased recruitment of macrophages,
T lymphocytes and mast cells in a lesion [30,31]. Macrophages are
critical in atherogenic initiation as they transform to foam cells. It
has been reported that the T lymphocyte deficiency reduces lesion
formation during moderate hypercholesterolemia [32]. Increased
Figure 5. Effect of H1-antihistamines on the expression of COX1, COX2, iNOS, eNOS and Egr1 mRNA in aorta. Aortic tissues harvested
from three or four mice from each group were analyzed for mRNA expression by qRT-PCR. Each gene amplicon was normalized for the b-actin
expression. Placebo (Pl), cetirizine low (C.L), cetirizine high (C.H), fexofenadine low (F.L) and fexofenadine high (F.H). Data presented are mean 6 SEM
of the fold change compared to control values. *p,0.05 vs. controls.
doi:10.1371/journal.pone.0102165.g005
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number of mast cells are known to be present in the adventitia of
atherosclerotic lesions [31]. In the present study, the increase in
lesion formation by low doses of cetirizine or fexofenadine was not
associated with an increased macrophage or T lymphocyte count.
High doses of these H1-antihistamines, on the other hand, were
found to reduce the macrophage content without changing the T
lymphocytes. Low dose of cetirizine or fexofenadine reduced mast
cell recruitment into the plaque area although the effect of
cetirizine was not statistically significant. This is opposite to the
contention that mast cells promote atherogenesis [19]. This
reduction in mast cell numbers in the plaque might be due to
increased degranulation. The amount of scavenger receptor CD36
was also found not to be affected by low doses of H1-
antihistamines.
Cytokines and chemokines derived from activated mast cells,
macrophages and other cell types have unique effects in
propagating proinflammatory and atherogenic signals. This study
provides insight into the alterations in serum cytokine and
chemokine levels in ApoE2/2 mice treated with H1-antihista-
mines. In the present study, concentrations of various proathero-
genic cytokines are altered by low dose of cetirizine or
fexofenadine (Table 3). Proatherogenic cytokines such as IL-1a
and MIP-3 levels are reduced in fexofenadine or cetirizine-treated
mice, respectively. In contrast, MIP-1a was increased in
Figure 6. Correlation of blood pressure variables with plaque to media ratio. Correlation analyses between systolic, diastolic and arterial
mean pressure values with the intima/media ratio of placebo, Pl (A), cetirizine low, C.L (B), cetirizine high, C.H (C), fexofenadine low, F.L (D) and
fexofenadine high, F.H (E). The ‘‘p’’ values and Pearson ‘‘r’’ values are given for each graph. ‘‘n’’ = 9 for panel A; ‘‘n’’ = 8 for panel B and E, and ‘‘n’’ = 6 for
panel C and D.
doi:10.1371/journal.pone.0102165.g006
Table 1. Blood pressure, heart rate and blood flow rate of ApoE2/2 mice treated with H1-antihistamines.
Treatment Systolic (mm Hg) Diastolic (mm Hg) Arterial Mean (mm Hg) Heart Rate (bpm) Flow (ml/min) Volume (ml)
Placebo (n = 10) 12764 8763 10163 716624 1161 4363
Cetirizine Low (n = 12) 12667 8666 9966 752617 1361 4863
Cetirizine High (n = 11) 12865 8665 9965 776628 1061 4565
Fexofenadine Low (n = 6) 12266 8368 9667 828654 1261 4766
Fexofenadine High (n = 8) 12563 8664 9863 772624 1162 4567
The blood pressure was monitored using non-invasive tail cuff method. Each value is mean 6 SEM.
doi:10.1371/journal.pone.0102165.t001
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fexofenadine treated mice. The levels of VEGF-a tended to
increase in both cetirizine and fexofenadine-treated mice. Proin-
flammatory cytokines such as TNF-a, IL-6, IFN-c were below
detectable levels in the cytokine array. In this study, the cytokine
array did not identify any particular cytokine or chemokine
responsible for the proatherogenic outcome of low dose H1-
antihistamines. Quantification of these putative cytokines using
high sensitivity assays are needed for conclusive interpretations.
We noted significant increases in iNOS and eNOS mRNA
expression in the aortic tissues of mice treated with high doses of
cetirizine or fexofenadine. Although we did not measure the levels
of nitric oxide in vasculature, we speculate that this may be nitric
oxide-mediated compensatory mechanism to regain the vascular
tone affected by H1R blocking. Furthermore, since nitric oxide is a
powerful vasodilator and inhibitor of platelet aggregation, it may
act as an antiatherogenic factor [33]. Thus, the relatively low level
expression of iNOS, eNOS, COX1 and COX2 in animals treated
with low dose cetirizine or fexofenadine suggests that these animals
may experience persistent vasoconstriction compared to high dose
H1-antihistamine-treated animals. In order to examine the
potential association between cetirizine or fexofenadine-mediated
changes in atheroma development and vascular functions, we
measured the blood pressure and associated parameters. We did
not find any difference in the blood pressure values between the
groups. However, the systolic, diastolic and mean arterial pressures
were positively correlated with lesion-media ratio at the aortic root
in low dose cetirizine-treated mice. Surprisingly a negative
correlation between blood pressure and lesion area was noted in
control mice. This may be explained by the ongoing histamine/
H1R mediated vasodilation in the absence of H1-antihistamines.
In respect to mice treated with high dose cetirizine or
fexofenadine, or low dose fexofenadine, there was no correlation
Table 2. Serum lipid and chemistry profile of ApoE2/2 mice treated with H1-antihistamines.
Parameters Placebo Cetirizine Low Cetirizine High Fexofenadine Low Fexofenadine High
Total cholesterol 1067 6 82(13) 1071 6 65(13) 964 6 96(6) 987 6 44(6) 781 6 64(6)
Triglycerides 189 6 20(16) 210 6 23(16) 177 6 16(6) 134 6 16(6) 226 6 23(6)
HDL Cholesterol 19 6 2(18) 20 6 3(18) 14 6 2(6) 18 6 1(6) 13 6 2(6)
LDL Cholesterol 208 6 7(7) 212 6 10(6) 213 6 10(4) 253 ± 8*(6) 188 6 6(2)
Glucose 213 6 17(13) 181 6 12(14) 209 6 35(2) 234 6 31(6) ND
CPK 2076 6 330(13) 659 ± 123**(14) ND 1117 ± 188*(6) ND
ALP 65.8 6 9(12) 55.3 6 6(12) ND 107 ± 21*(6) ND
SGOT 281 6 22(13) 212 6 22(15) 362 6 115(2) 242 6 37(6) ND
SGPT 132 6 20(12) 116 6 16(15) 107 6 30(2) 201 6 57(6) ND
ND = not determined, Each value is mean ± SEM *p,0.05 and **p,.005.
doi:10.1371/journal.pone.0102165.t002
Table 3. Serum cytokines.
Cytokines Placebo Cetirizine Low Fexofenadine Low
Eotaxin (pg/ml) 11946186 834650 11956103
IL-1a (pg/ml) 376±60 291±52 197±40*
IL-1b (ng/ml) 6.46.4 7.360.8 7.160.4
IL-18 (ng/ml) 22.361.3 25.561.6 23.561.4
M-CSF-1 (ng/ml) 13.060.7 12.860.5 11.760.2
MIP-1a (ng/ml) 7.2±0.1 8.1±0.4 8.2±0.2*
MIP-1b (pg/ml) 545649 593663 627675
MIP-2 (pg/ml) 130645 59619 86614
MIP-3 (ng/ml) 4.3±0.2 3.5±0.2* 4.6±0.2
MCP-1 (pg/ml) 115618 105622 166624
MCP-3 (pg/ml) 125617 99613 13967
MCP-5 (ng/ml) 9.0606 12.062.5 8.861.7
SCF (pg/ml) 793665 9076125 865655
TIMP1 (ng/ml) 1.260.2 0.960.1 1.060.1
Thrombopoeitin (ng/ml) 78.065.7 78.268.1 76.064.4
VEGF-a (pg/ml) 277611.6 317639 327612
EGF (pg/ml) 88.7620.3 69.768.3 83.0612.3
GRO-a protein (ng/ml) 0.20±0.04 0.09±0.01* 0.14±0.01
Serum cytokines were determined by cytokine array commercially at IDEXX Preclinical Research Services. Each value is mean ± SEM *p,0.05.
doi:10.1371/journal.pone.0102165.t003
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between blood pressure and lesion-media ratio. This may be
attributed to increased vasodilatory effects induced by increases in
nitric oxide levels derived from overexpressed eNOS and/or
iNOS.
Hypercholesterolemia is a characteristic feature of atheroscle-
rosis in mouse models and humans, although the condition does
not always correlate with the progression of the disease [20,34,35].
In this study, the serum levels of triglycerides, total cholesterol,
LDL, HDL, and VLDL were not altered in the ApoE2/2 mice
treated with low dose cetirizine although these animals had
increased atherosclerotic plaque area. On the other hand, low
dose fexofenadine significantly increased LDL cholesterol levels.
This suggests that lipid derangement may be a cause in
fexofenadine, but not in cetirizine-induced increase in atheroscle-
rosis.
In summary, the low therapeutic doses of cetirizine or
fexofenadine increase atherosclerotic lesion formation in
ApoE2/2 mice maintained on a high fat diet for three months.
Interestingly, ApoE2/2 mice treated with high doses of cetirizine
or fexofenadine did not increase plaque development when
compared to controls. It should be noted that increased
atherosclerosis by low dose cetirizine was not associated with lipid
derangements. But low dose of fexofenadine showed an increase in
LDL cholesterol levels which correlated with atherosclerosis.
However, we noted a positive correlation between blood pressure
and lesion area in low dose cetirizine- treated mice. The high doses
of cetirizine and fexofenadine may be initiating a compensatory
vasodilatory pathway through nitric oxide. It should be empha-
sized that, in contrast to the effect of mepyramine [16], neither
cetirizine nor fexofenadine, even at high doses prevented or
reduced atherosclerosis progression in ApoE2/2 mice. It is possible
that, in addition to H1-antihistaminic properties, other chemical
characteristics unique to these H1-antihistamines may play a role
in the proatherogenic effects.
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Figure 7. Effect of H1-antihistamines on levels of prostanoids and histamine. 24-h urine samples were analyzed for the concentration of
stable metabolites of TxA2 (A), PGI2 (B) by GC-MS or EIA. Urinary levels of histamine were measured by EIA (C). Results shown are mean 6 SEM. n = 4
to 12. None of the parameters found to be significant.
doi:10.1371/journal.pone.0102165.g007
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